hero

Opportunities in the Upfront Portfolio

78
companies
359
Jobs
Switch Therapeutics
Switch Therapeutics
switchthera.com

Locations

San Francisco, CA, USA

industry

Biotechnology · DeepTech · Health

Size

11-50 employees

Stage

Series A

founded in

2020

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch’s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch’s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company’s South San Francisco based team has continued to grow as its research has advanced.

Something looks off?
Open jobs at Switch Therapeutics
Powered by Getro